Ionis Pharmaceuticals IONS Interest Expense Related To Sale Of Future Royalties
Interest Expense Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:InterestExpenseRelatedToSaleOfFutureRoyalties.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's interest expense related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's interest expense related to sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported interest expense related to sale of future royalties of $17.18M in Q1 2026.
- How has Ionis Pharmaceuticals's interest expense related to sale of future royalties changed year-over-year?
- Ionis Pharmaceuticals's interest expense related to sale of future royalties decreased by 8.0% year-over-year, from $18.67M to $17.18M.
- What does interest expense related to sale of future royalties mean?
- The cost of borrowing money that is repaid through future royalty income.
- How do you interpret interest expense related to sale of future royalties?
- High interest expense here indicates a significant reliance on royalty monetization as a non-dilutive funding source.
- How does interest expense related to sale of future royalties compare across companies?
- Unique to biotech and pharma companies that monetize drug pipelines to fund ongoing R&D.